Potential Acquisition

RNS Number : 0439Y

Advanced Oncotherapy PLC

18 February 2013

 



18 February 2013

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Potential Acquisition

The Board of Advanced Oncotherapy is pleased to announce that it has signed heads of terms to make a substantial acquisition of a company that has developed state of the art technology for treating cancerous tumours using affordable, cost-effective proton therapy techniques.  The consideration for the proposed acquisition is to be satisfied by the issue of new Ordinary Shares in the Company.  The acquisition is subject, inter alia, to the completion of mutual due diligence by both parties.

Proton Beam Therapy (PBT) is the radiation treatment of choice for very many cancers, in particular those effecting children as it can be focused and delivered to the tumour very precisely.  This avoids harm to nearby critical organs and tissues so reducing the side effects commonly associated with traditional radiation therapies.  Currently because of the size and historic cost of PBT facilities there are only 32 Centres operating around the world.

Advanced Oncotherapy's target acquisition has, with one of the world's leading scientific establishments, concentrated on developing a low cost affordable system capable of providing PBT treatment to a large number of hospitals. In this novel technology - based on radio frequency linear accelerators (linacs) - no absorber is needed to adjust the energy to the depth of the tumour (at variance with all cyclotrons) and this adjustment can be made electronically in only one hundredth of a second (instead of the second required by synchrotrons). With more than a hundred dose deliveries per second the target can be 'painted' at least ten times, thus applying the best possible technique to irradiate moving tumours, which is the frontier of modern radiotherapy.

Linacs have other important advantages: they are made of ten practically identical modules, which are very well suited for cost reductions in mass production; they are very light and can be pre-mounted before transportation, with a significant reduction in the installation time on site; they contain no adjustable component and are thus easy to maintain; they are powered by conventional modulator/klystron systems similar to the many thousands already used to power the electron linacs used in conventional radiotherapy; they can be locally shielded so the concrete walls of the vault can be significantly thinner than the ones needed for cyclotrons and synchrotrons.

Further announcements will be made in due course.

For further information, please contact:

Michael Sinclair, Chief Executive	Sandy Jamieson	Jon Levinson	Simon Hudson
Advanced Oncotherapy Plc	Libertas Capital Corporate Finance Ltd	Peterhouse Corporate Finance	Tavistock Communications
	(NOMAD & Joint Broker)	(Joint Broker)	(Financial PR & IR)
020 7920 3150	020 7569 9650	020 7469 0930	020 7920 3150

About Advanced Oncotherapy

Advanced Oncotherapy is a provider of new technology for innovative and patient-focused cancer treatments in the UK.  These are technologies endorsed internationally by UK and global cancer clinicians, but not currently available in the NHS nor the private sector.  Such initiatives build on the Group's 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its Oncotherapy Resources business focused on early stage breast cancer treatment.  Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK and has secured planning approval for its first proton beam therapy center in the UK in the City of London.

-ends-

 

END

 

 

ACQUVRBRONAUAAR